Home > Insider Trading > Filing (0000899243-19-013252)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1563880	Trevi Therapeutics Inc.	TRVI	Pharmaceutical Preparations (2834)	450834299

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1774767	Foundation Mellon King Richard	C/O Trevi Therapeutics, Inc. 195 Church Street, 14Th Floor New Haven CT 06510		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-05-09	222,816	$0.00	222,816	No	4	C	Direct
Common Stock	Acquisiton	2019-05-09	24,341	$0.00	247,157	No	4	J	Direct
Common Stock	Acquisiton	2019-05-09	100,000	$10.00	347,157	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	J	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2019-05-09	1,908,450	$0.00	222,816	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Consists of shares transferred to Richard King Mellon Foundation by TPG Biotechnology Partners III, L.P. in connection with the closing of the Issuer's initial public offering.